Biogen is an American multinational biotechnology company headquartered in Cambridge, Massachusetts, focused on treatments for neurological diseases. Founded in 1978, the company markets therapies across multiple neurology indications and is publicly traded on Nasdaq.
Aclaris Therapeutics outlined its TSLP antibody and ITK kinase pipeline at the Guggenheim Biotech Summit, with Phase II AD results for bosakitug due in late 2026 and Phase 1b studies for bispecific ATI-052 underway. The company will also announce Phase 1a results for ATI-052 and lead indication selection for ATI-2138 on April 28, 2026.
Biogen announced that litifilimab received FDA Breakthrough Therapy Designation for cutaneous lupus erythematosus and will present Phase 2 AMETHYST study results at the 2026 AAD Annual Meeting, with Phase 3 data expected in 2027.
The global biotechnology market is undergoing a transformation from discovery-based science to precision engineering, driven by AI, synthetic biology, and gene editing technologies, with projected growth of 13-15% over the next five years.
Stoke Therapeutics presented long-term Dravet syndrome data showing up to 80% seizure reductions sustained through three years, outlined its Phase 3 EMPEROR trial design targeting mid-2027 data, and disclosed first patient dosing in its ADOA program.
A single blood test measuring p-tau217 protein can predict when cognitively unimpaired individuals will develop Alzheimer's symptoms, with a margin of error of 3-4 years, potentially accelerating clinical trials.
Dr Reddy's and Biocon plan to launch generic versions of Novo Nordisk's weight-loss drugs at up to 60% below branded prices as semaglutide patents expire, targeting a global market projected to reach $150 billion by the early 2030s.
Samsung Bioepis and Regeneron reached a settlement allowing U.S. launch of Opuviz, an aflibercept biosimilar, in January 2027. The agreement resolves a patent dispute that began in late 2023.
SCOPE 2026 in Orlando recognized innovation in clinical research with three awards programs, honoring Biogen's lupus webinar series, TrialScreen's site connection initiative, and Biorce's AI platform among 70 competing products.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07483632 |
A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07444489 |
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) |
ENROLLING_BY_INVITATION | PHASE3 |
| NCT07444476 |
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam |
RECRUITING | PHASE3 |
| NCT07444450 |
A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec |
NOT_YET_RECRUITING | PHASE3 |
| NCT07444333 |
Cardiac Output and Fatigue in Friedreich's Ataxia |
NOT_YET_RECRUITING | NA |
| NCT07433010 |
German Dementia Registry |
RECRUITING | |
| NCT07400198 |
Gait and Bone Health in SMA |
RECRUITING | |
| NCT07398469 |
A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone |
RECRUITING | |
| NCT07297199 |
A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55 |
COMPLETED | PHASE1 |
| NCT07294144 |
Tofersen in Non-SOD1 ALS |
RECRUITING | PHASE2 |
